EASI-Genomics was launched earlier this year to provide free access to NGS technologies and genomic services to researchers from industry and academia.
The signature is enriched for genes involved in immune-related processes, such as T cell co-stimulation and antigen presentation, and suggests personalized treatments.
With available brain data, researchers came up with expression prediction models for finding new schizophrenia-related genes in a larger case-control set.
Clear Labs will implement Oxford Nanopore's GridIon nanopore sequencing instrument with its Clear Safety platform to detect food-borne pathogens.
Horizon will help develop the cell line-derived reference material, St. George's will provide clinical samples, and the EMQN will run a validation study.
Last week, GenomeWeb's readers were most interested in Oxford Nanopore's launch of its Flongle flow cell adapter.
A brief recap of Genetics/Genomics news the week of Mar 22, 2019: Novogene, Hologic, Agilent, and Diagenode
Researchers identified a handful of microbes associated with spontaneous preterm birth, and highlighted host immune protein levels with potential ties to the condition.
Under a proposed decision, to be finalized in August and become effective in late 2020, NIPT would only be covered for women with particular fetal trisomy risks.
Based on PCR technology acquired from Hain Diagnostics, the test and platform enable rapid detection of TB, as well as assessment of antibiotic resistance.
With single-cell genome sequencing, recombination assays, and other approaches in mouse cells, researchers identified factors affecting DNA crossover.
The study adds to growing evidence around the utility of cell-free DNA testing in lung cancer patients, while highlighting shortcomings of the approach.
Sequencing analysis of the Enterococcus faecium isolates found that they belonged to two clades, one of which harbored numerous resistance genes.
Molecular features in primary and recurrent glioblastomas indicated that key initiator mutations turned up years before diagnosis, often persisting in recurrent tumors.
The Navify software, which Roche launched today, provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.
The test detects Group A Strep in throat swab samples using the firm's rapid molecular diagnostics instrument called Revogene.
The companies will use their respective technologies in a study investigating the associations between ovarian cancer and the gut microbiome.
Researchers designed a PCR-based test for pyrethroid resistance based on a cytochrome P450 allele that is common in Anopheles funestus mosquitoes from Malawi.
Researchers reported finding oncohistone mutations within nearly 4 percent of tumors and said they could alter the structure and function of chromatin.
With RNA sequencing and other data, researchers gauged neoantigen formation, immunoediting, and clonal evolution in non-small cell lung cancers.
With ancient mitochondrial sequences from all seven Canary Islands, researchers identified at least two early migrations involving shifting populations from North Africa.
The company said it will offer 4.5 million shares for $23 per share and intends to use the net proceeds for working capital and general corporate purposes.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.